Skip to main content

Advertisement

Log in

THYROID DISEASE

Insights into immune checkpoint inhibitor-induced thyroiditis

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Immune checkpoint inhibitor therapies induce potent anti-tumour immunity as well as immune-related adverse events that manifest as autoimmune disease — particularly thyroiditis. Translational studies and preclinical models are beginning to unravel the molecular processes that mediate these adverse events; this knowledge might enable the development of ICIs with anti-tumour efficacy and improved safety margins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Shankar, B. et al. Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer. JAMA Oncol. 6, 1952–1956 (2020).

    Article  PubMed  Google Scholar 

  2. Muir, C. A. et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J. Clin. Endocrinol. Metab. https://doi.org/10.1210/clinem/dgab263 (2021).

    Article  PubMed  Google Scholar 

  3. Yasuda, Y. et al. CD4+ T cells are essential for the development of destructive thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice. Sci. Trans. Med. 13, eabb7495 (2021).

    Article  CAS  Google Scholar 

  4. Fan, Y. et al. Association of immune related adverse events with efficacy of immune checkpoint inhibitors and overall survival in cancers: a systemic review and meta-analysis. Front. Oncol. 11, 633032 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Liu, J. et al. Assessing immune-related adverse events of efficacious combination immunotherapies in preclinical models of cancer. Cancer Res. 76, 5288–5301 (2016).

    Article  CAS  PubMed  Google Scholar 

  6. Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428–432 (2019).

    Article  CAS  PubMed  Google Scholar 

  7. Sharma, R., Di Dalmazi, G. & Caturegli, P. Exacerbation of autoimmune thyroiditis by CTLA-4 blockade: a role for IFNγ-induced indoleamine 2, 3-dioxygenase. Thyroid 26, 1117–1124 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Álvarez-Sierra, D. et al. Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J. Autoimmun. 103, 102285 (2019).

    Article  PubMed  Google Scholar 

  9. Kotwal, A. et al. Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. Thyroid 30, 1440–1450 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Horie, I. et al. Induction of autoimmune thyroiditis by depletion of CD4+CD25+ regulatory T cells in thyroiditis-resistant IL-17, but not interferon-γ receptor, knockout nonobese diabetic-H2 h4 mice. Endocrinology 152, 4448–4454 (2011).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mabel Ryder.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lechner, M.G., Ryder, M. Insights into immune checkpoint inhibitor-induced thyroiditis. Nat Rev Endocrinol 17, 643–644 (2021). https://doi.org/10.1038/s41574-021-00557-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-021-00557-3

  • Springer Nature Limited

Navigation